Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat

International Journal of Cancer

Volumn 118, Issue 1, 2006, Pages 215-221

  Ogata, Yutaka ^a   Matono, Keiko ^a   Nakajima, Motowo ^b   Sasatomi, Teruo ^a   Mizobe, Tomoaki ^a   Nagase, Hideaki ^c   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Postoperative adjuvant therapy; Preclinical lung metastases model

Indexed keywords

CYCLINE; MATRIX METALLOPROTEINASE INHIBITOR; MMI 270; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; CHEMOPREVENTION; COLONIC NEOPLASMS; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; NEOPLASM CIRCULATING CELLS; NEOVASCULARIZATION, PATHOLOGIC; PYRAZINES; RATS; RATS, NUDE; SULFONAMIDES; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 27944506838     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21285     Document Type: Article

References (37)

1. Tong D, Russell AH, Dawson LE, Wisbeck W. Second laparotomy for proximal colon cancer: sites of recurrence and implications for adjuvant therapy. Am J Surg 1983;145:382-6.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA. Cancer J Clin 2000;50:7-33.
3. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
5. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;84:4-6.
6. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
7. Ahmed MH, Arai T, Konno H, Nahar L, Tanaka T, Izumiyama N, Takubo K, Nakamura S, Baba S. Regression of metastatic liver tumors in rats treated with angiogenesis inhibitor TNP-470: occurrence of apoptosis and necrosis. Jpn J Cancer Res 1997;88:977-81.
8. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S. Prevention of hepatic metastasis of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995;55:836-9.
9. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9.
10. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
11. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252-8.
12. Naglich JG, Jure-Kunkel M, Gupta E, Fargnoli J, Henderson AJ, Lewin AC, Talbott R, Baxter A, Bird J, Savopoulos R, Wills R, Kramer RA, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001;61:8480-5.
13. Wood JM, Muller M, Schnell C, Cozens RM, O'Reilly T, Cox D, Ganu V, Melton R, Parker DT, Macpherson LJ, Nakajima M, Reich R. CGS27023A, a potent and orally active matrix metalloproteinases inhibitor with antitumor activity. Proc Am Assoc Cancer Res 1998;39:83.
14. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22.
15. Oda H, Ogata Y, Shirouzu K. The effect of angiogenesis inhibitor TNP-470 against postoperative lung metastasis following removal of orthotopic transplanted human colon cancer. Kurume Med J 2001;48:285-93.
16. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988;48:6863-71.
17. Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T, Okada Y. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994;81:69-77.
18. Yamauchi K, Ogata Y, Nagase H, Shirouzu K. Reduction in liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP-1 gene into KM12SM cells. Surg Today 2001;31:791-8.
19. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the promatrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995;270:18506-11.
20. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990;194:721-30.
21. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980;283:139-46.
22. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
23. Liotta L, Kleinerman J, Saldel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
24. Starky JR, Crowle PK, Taubenberger S. Mast-cell-deficient W/W mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 1988;42:48-52.
25. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
26. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-21.
27. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA. Marimastat Pancreatic Cancer Study Group. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-55.
28. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995;55:3629-33.
29. Watson SA, Morris TM, Parsons SL, Steele RJ, Brown PD. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Br J Cancer 1996;74:1354-8.
30. Aparicio T, Kermorgant S, Dessirier V, Lewin MJ, Lehy T. Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats. Carcinogenesis 1999;20:1445-51.
31. An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, et al. Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis 1997;15:184-95.
32. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252-8.
33. Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, Johnson PW, Neoptolemos JP, Baillet M, Barker K, Berrington A, Brown PD, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer 1999;79:509-14.
34. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4:1101-9.
35. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004;22:4683-90.
36. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7.
37. Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S, Choi L, Twelves C. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 2005;55:39-46.